Keratitis sicca (autoimmune) - Symptoms, Causes, Treatment & Prevention

Overview

Keratitis sicca, also known as “dry eye keratitis,” refers to inflammation of the cornea that results from chronic ocular surface dryness. When the underlying cause is an autoimmune disorder—most commonly Sjögren’s syndrome, rheumatoid arthritis, systemic lupus erythematosus, or Stevens‑Johnson syndrome—the condition is termed “autoimmune keratitis sicca.” The immune system attacks the lacrimal glands and ocular surface tissues, leading to insufficient tear production, tear film instability, and, ultimately, corneal damage.

Autoimmune keratitis sicca can affect anyone, but it is most prevalent in middle‑aged to older adults, especially women. Epidemiologic data estimate that:

• Dry eye disease (DED) affects 5–30% of the worldwide adult population, with higher rates in Asian countries (up to 33%).
• Approximately 30–40% of patients with Sjögren’s syndrome develop keratitis sicca.
• Women are 8–10 times more likely than men to develop autoimmune‑related dry eye because many of the associated systemic diseases have a strong female predilection.

While keratitis sicca itself is rarely life‑threatening, chronic inflammation can lead to permanent visual impairment if not recognized and managed promptly.

Symptoms

Symptoms arise from both tear deficiency and corneal inflammation. They may be mild initially but can progress rapidly.

• Persistent ocular dryness – a gritty or sand‑like sensation.
• Burning or stinging pain – often worsens in windy, dry, or air‑conditioned environments.
• Redness – conjunctival hyperemia (eye redness) due to irritation.
• Blurred vision – especially after reading, screen time, or exposure to bright light.
• Fluctuating vision – tear film instability can cause the visual acuity to change throughout the day.
• Photophobia – heightened sensitivity to light.
• Excessive tearing (reflex tearing) – a paradoxical response to severe dryness.
• Foreign‑body sensation – the feeling that something is stuck in the eye.
• Sticky or crusted eyelids – especially upon waking.
• Eye fatigue – difficulty keeping the eyes open for long periods.
• Corneal epithelial defects – may present as a spot of whiteness or a small ulcer on the cornea.

When the cornea becomes ulcerated or infected, symptoms can escalate to severe pain, watery discharge, and vision loss, requiring urgent care.

Causes and Risk Factors

Autoimmune keratitis sicca is a secondary manifestation of systemic immune dysregulation. The primary mechanisms include:

• Lacrimal gland infiltration by autoreactive T‑cells leading to reduced aqueous tear production.
• Meibomian gland dysfunction caused by inflammatory cytokines, decreasing the lipid layer of the tear film.
• Altered mucin secretion from conjunctival goblet cells, compromising tear film stability.
• Elevated inflammatory mediators (e.g., interleukin‑1, tumor necrosis factor‑α) on the ocular surface, directly damaging corneal epithelium.

Key Autoimmune Disorders Associated with Keratitis Sicca

• Sjögren’s syndrome (primary or secondary)
• Rheumatoid arthritis
• Systemic lupus erythematosus (SLE)
• Scleroderma
• Graves’ disease
• Vogt‑Koyanagi‑Harada disease
• Stevens‑Johnson syndrome / Toxic epidermal necrolysis (post‑drug reactions)

Additional Risk Factors

• Female sex (especially ages 40–70)
• Hormonal changes (menopause, hormone replacement therapy)
• Contact lens wear, especially extended‑wear lenses
• Environmental exposure: low humidity, wind, smoke, or pollutants
• Medications that reduce tear production (e.g., antihistamines, antidepressants, isotretinoin, diuretics)
• Previous ocular surgery (LASIK, cataract extraction) that disrupts corneal nerves

Diagnosis

Accurate diagnosis requires a combination of patient history, clinical examination, and objective testing.

History and Physical Examination

• Detailed review of systemic autoimmune disease, medication list, and environmental exposures.
• Assessment of symptom duration, triggers, and severity using validated questionnaires (e.g., Ocular Surface Disease Index – OSDI).
• Slit‑lamp biomicroscopy to evaluate:
  • Conjunctival redness, papillae, or filaments.
  • Corneal staining patterns with fluorescein or lissamine green.
  • Presence of punctate epithelial erosions, ulceration, or scarring.

Objective Tests

• Schirmer I test (without anesthesia) – measures basal and reflex tear production; ≤5 mm in 5 min suggests severe dry eye.
• Tear Break‑Up Time (TBUT) – assesses tear film stability; <8 seconds is abnormal.
• Ocular Surface Staining – fluorescein, rose bengal, or lissamine green pinpoint areas of epithelial damage.
• Meibography – infrared imaging of Meibomian glands to detect dropout or obstruction.
• Ocular surface interferometry – evaluates lipid layer thickness.
• Inflammatory marker testing – tear cytokine analysis (IL‑6, MMP‑9) can support an inflammatory etiology, though not routinely required.
• Serologic work‑up – ANA, rheumatoid factor, anti‑SSA/SSB antibodies when an underlying autoimmune disorder is suspected.

Differential Diagnosis

Conditions that can mimic keratitis sicca include infectious keratitis, allergic conjunctivitis, ocular rosacea, and neurotrophic keratitis. Proper differentiation is essential to avoid inappropriate treatments such as antibiotics for a non‑infectious process.

Treatment Options

Treatment is tiered—from basic lubricants to systemic immunomodulation—aimed at restoring tear film, reducing inflammation, and protecting the cornea.

1. Artificial Tears and Lubricants

• Preservative‑free lubricating drops (e.g., carboxymethylcellulose, hyaluronic acid) – 4–6 times daily.
• Gel or ointment formulations at night to maintain a moist environment.
• Artificial tear “puffs” (e.g., Refresh® Optive®) for patients who need prolonged relief.

2. Anti‑Inflammatory Topicals

• Corticosteroid eye drops (e.g., loteprednol, fluorometholone) – short‑term use for acute flare‑ups; monitor intra‑ocular pressure.
• Cycloplegic agents (e.g., cyclosporine 0.05% – Restasis®, lifitegrast 5% – Xiidra®) – improve tear production and reduce ocular surface inflammation. Benefits may appear after 4–12 weeks.
• Topical tetracycline or doxycycline (low‑dose oral) – helps treat Meibomian gland dysfunction by inhibiting matrix metalloproteinases.

3. Punctal Occlusion

Insertion of silicone or collagen punctal plugs reduces tear drainage, increasing tear residence time. Temporary (Day-O) plugs can be trialed before permanent devices.

4. Autologous Serum Eye Drops

Serum derived from the patient’s own blood contains growth factors and vitamins that promote epithelial healing. Typically prepared at 20% concentration and used 4–6 times daily for severe cases.

5. Systemic Immunomodulatory Therapy

• Hydroxychloroquine – commonly used in Sjögren’s and lupus; may improve tear production.
• Systemic glucocorticoids – short bursts for severe inflammation; long‑term use limited due to side effects.
• Biologic agents (e.g., rituximab, abatacept) – reserved for refractory disease under rheumatology supervision.

6. Procedures and Advanced Therapies

• Lacrimal gland “Dacryoadenectomy” – Rarely performed, only in cases of refractory severe dry eye with gland hypertrophy.
• Amniotic membrane transplantation – provides a biological bandage for non‑healing corneal epithelial defects.
• Intense pulsed light (IPL) therapy – shown to improve Meibomian gland function in ocular rosacea‑associated dry eye.

7. Lifestyle and Environmental Modifications

• Humidifier use (≥40% relative humidity) at home and work.
• Frequent “blink exercises” during screen time (20‑20‑20 rule).
• Avoid smoke, wind, and direct air‑conditioning.
• Omega‑3 fatty acid supplementation (1 g EPA/DHA daily) can enhance Meibomian gland secretions (evidence grade B).

Living with Keratitis sicca (autoimmune)

Managing a chronic ocular surface disease requires consistent daily habits and coordination between ophthalmology, rheumatology, and primary care.

Daily Management Checklist

1. Morning routine – Apply preservative‑free artificial tears, inspect punctal plugs, and perform a quick fluorescein check for any new staining.
2. Screen breaks – Every 20 minutes, look at an object 20 feet away for 20 seconds; blink deliberately.
3. Mid‑day hydration – Drink at least 8 glasses of water; dehydration worsens tear osmolarity.
4. Evening care – Use lubricating ointment before bed; consider a night‑time humidifier.
5. Medication log – Keep a diary of eye drops, systemic meds, and any side effects (e.g., pressure spikes from steroids).
6. Follow‑up schedule – Typically every 3–4 months, or sooner if symptoms flare.

Psychological and Social Support

Chronic eye discomfort can affect concentration, mood, and quality of life. Patients benefit from:

• Support groups for Sjögren’s or rheumatoid arthritis.
• Occupational therapy for visual ergonomics.
• Stress‑reduction techniques (meditation, yoga) that may lower systemic inflammation.

Prevention

Because autoimmune keratitis sicca is largely driven by systemic disease, primary prevention centers on disease control and ocular surface protection.

• Early diagnosis and treatment of underlying autoimmune conditions (e.g., timely initiation of disease‑modifying anti‑rheumatic drugs for rheumatoid arthritis).
• Regular ophthalmic evaluations for patients with known systemic autoimmune disease—at least annually.
• Limit exposure to known tear‑drying medications; discuss alternatives with your physician.
• Adopt protective eyewear outdoors to shield eyes from wind and UV radiation.
• Maintain a balanced diet rich in omega‑3 fatty acids, antioxidants (vitamins A, C, E), and adequate hydration.

Complications

If left untreated, chronic keratitis sicca can progress to serious ocular morbidity:

• Corneal ulceration – leads to scarring and permanent visual loss.
• Superimposed bacterial or fungal infection – especially in epithelial defects.
• Neovascularization – ingrowth of blood vessels into the cornea, compromising transparency.
• Symblepharon – adhesion of the eyelid to the globe, restricting eye movement.
• Secondary glaucoma – prolonged steroid use may raise intra‑ocular pressure.
• Reduced quality of life – chronic pain, reading difficulty, and work productivity loss.

When to Seek Emergency Care

References

• Mayo Clinic. “Dry eye (keratoconjunctivitis sicca).” Accessed July 2026.
• American Academy of Ophthalmology. “Dry Eye Disease Clinical Practice Guidelines.” 2022.
• World Health Organization. “Global estimates of the prevalence of dry eye disease.” *WHO Vision Report*, 2023.
• National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). “Sjogren’s Syndrome.” 2025.
• Cleveland Clinic. “Keratitis Sicca (Dry Eye) Treatment Options.” 2024.
• Jones L, et al. “Impact of systemic immunosuppression on ocular surface disease in Sjögren’s syndrome.” *Ophthalmology*, 2022;129(9): 1065‑1072.
• Foster CS, et al. “Omega‑3 fatty acids for dry eye disease: A meta‑analysis.” *JAMA Ophthalmology*, 2021;139(6): 642‑650.